Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Alcon Inc (ALC)

Alcon Inc (ALC)
92.50 +0.53 (+0.58%) 02/28/25 [NYSE]
89.75 x 100 92.50 x 200
Realtime by (Cboe BZX)
89.75 x 100 92.50 x 200
Realtime 92.50 unch (unch) 16:55 ET
Quote Overview for Fri, Feb 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
91.68
Day High
92.84
Open 92.09
Previous Close 91.97 91.97
Volume 1,259,100 1,259,100
Avg Vol 1,779,365 1,779,365
Stochastic %K 64.35% 64.35%
Weighted Alpha +7.05 +7.05
5-Day Change +2.19 (+2.42%) +2.19 (+2.42%)
52-Week Range 77.54 - 101.10 77.54 - 101.10
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,625,072
  • Shares Outstanding, K 493,244
  • Annual Sales, $ 9,455 M
  • Annual Income, $ 974,000 K
  • EBIT $ 1,226 M
  • EBITDA $ 2,452 M
  • 60-Month Beta 0.99
  • Price/Sales 4.58
  • Price/Cash Flow 16.55
  • Price/Book 2.10

Options Overview Details

View History
  • Implied Volatility 23.26% ( -0.57%)
  • Historical Volatility 24.32%
  • IV Percentile 56%
  • IV Rank 44.69%
  • IV High 34.36% on 02/24/25
  • IV Low 14.30% on 03/15/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 939
  • Volume Avg (30-Day) 1,400
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 15,515
  • Open Int (30-Day) 9,821

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.78
  • Number of Estimates 5
  • High Estimate 0.83
  • Low Estimate 0.73
  • Prior Year 0.78
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.60 +5.59%
on 02/12/25
Period Open: 91.26
95.36 -3.00%
on 02/26/25
+1.24 (+1.36%)
since 01/28/25
3-Month
82.31 +12.38%
on 01/14/25
Period Open: 88.23
95.36 -3.00%
on 02/26/25
+4.27 (+4.84%)
since 11/27/24
52-Week
77.54 +19.29%
on 04/30/24
Period Open: 85.69
101.10 -8.51%
on 09/12/24
+6.81 (+7.95%)
since 02/28/24

Most Recent Stories

More News
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours

Alcon, Inc. ALC delivered fourth-quarter 2024 core earnings per share (EPS) of 72 cents, up 2.9% from the year-ago quarter’s figure (up 3% at constant exchange rate or CER). The figure topped the Zacks...

RMD : 233.52 (+0.97%)
ALC : 92.50 (+0.58%)
PODD : 272.27 (+1.94%)
CAH : 129.48 (+1.58%)
Do Options Traders Know Something About Alcon (ALC) Stock We Don't?

Investors in Alcon Inc. ALC need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2025 $92.5 Put had some of the highest implied volatility of...

ALC : 92.50 (+0.58%)
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

Alcon, Inc. ALC delivered core earnings per share (EPS) of 81 cents for the third quarter of 2024, up 22.7% from the year-ago quarter’s figure (up 25% at the constant exchange rate or CER). The figure...

DGX : 172.90 (+0.79%)
BSX : 103.79 (+2.97%)
RMD : 233.52 (+0.97%)
ALC : 92.50 (+0.58%)
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.

ALC : 92.50 (+0.58%)
BLCO : 16.00 (+1.27%)
BHC : 7.44 (-2.75%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.2599 (+9.56%)
ALC : 92.50 (+0.58%)
BLCO : 16.00 (+1.27%)
JNJ : 165.02 (+0.79%)
RHHBY : 41.7400 (+0.72%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.2599 (+9.56%)
ALC : 92.50 (+0.58%)
BLCO : 16.00 (+1.27%)
JNJ : 165.02 (+0.79%)
RHHBY : 41.7400 (+0.72%)
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 124.92 (+3.97%)
X : 40.22 (+3.26%)
MNDY : 296.77 (+0.07%)
TSLA : 292.98 (+3.91%)
KEY : 17.32 (+2.00%)
CMA : 64.33 (+1.23%)
HD : 396.60 (+1.62%)
SU : 38.28 (+0.21%)
ALC : 92.50 (+0.58%)
A : 127.92 (+0.66%)
New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the American Society of Cataract and Refractive Surgery...

ALC : 92.50 (+0.58%)
Alcon Announces Results of 2023 Annual General Meeting

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM)....

ALC : 92.50 (+0.58%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 14.9000 (+9.48%)
MNMD : 6.72 (+0.30%)
INCY : 73.50 (+0.44%)
SGEN : 228.74 (-0.07%)
PFE : 26.43 (+1.26%)
FBRX : 9.10 (-2.15%)
JAZZ : 143.53 (+0.18%)
ALC : 92.50 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma...

See More

Key Turning Points

3rd Resistance Point 94.17
2nd Resistance Point 93.50
1st Resistance Point 93.00
Last Price 92.50
1st Support Level 91.84
2nd Support Level 91.17
3rd Support Level 90.67

See More

52-Week High 101.10
Last Price 92.50
Fibonacci 61.8% 92.10
Fibonacci 50% 89.32
Fibonacci 38.2% 86.54
52-Week Low 77.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements